Hanmi Pharm cruising with global clinical trials of 3 next-gen anticancer drugs

Published: 2018-06-08 18:26:27

Updated: 2018-06-08 18:26:27

The research data about drug candidates for next-generation anticancer drugs developed by Hanmi Pharm was presented at the 2018 American Society of Clinical Oncology held in Chicago between the last 1^st and 5^th.

The drug candidates for new anticancer drugs presented at the ASCO were: Spectrum Pharmaceuticals long-acting neutropenia therapy Rolontis, targeted therapy for cancer Poziotinib and A...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.